Those of us in the business of defending clients in toxic tort and pharmaceutical product liability cases often take it for granted that pronouncements by regulatory agencies regarding risk are distinct and quite different in key ways from what is required in civil litigation for proof of causation. But how are they different, why are they different and where is the evidence that they are intended to be different?
Read the full article here.
Comments